Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.49 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | GHSR | Q92847 | 3/20 | 0.47 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256987 | 0.88 | OPRD1 (0.61) | OPRM1OPRD1OPRK1 | |
| Kifgslafl SCHEMBL29356758 | 0.81 | BACE1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31433367 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL29623290 | 0.81 | VIPR2 (0.65) | GHSRVIPR1 | |
| SCHEMBL29419673 | 0.80 | OPRD1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31257081 | 0.80 | OPRD1 (0.64) | OPRM1OPRD1OPRK1 | |
| SCHEMBL18854322 | 0.79 | IL23R (0.60) | IL23RRENGHSR | |
| SCHEMBL30799723 | 0.79 | OPRK1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL38662535 | 0.79 | OPRM1 (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31257045 | 0.79 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | claimed |
| US-20250242086-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-07-31 | — | — | US | claimed |
| WO-2024168133-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF MIAMI (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2023219948-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-11-16 | — | — | WO | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-12534536-B2 | Natural killer cells expressing a chimeric antigen receptor that binds CD38 | ONK THERAPEUTICS LIMITED (IE) | 2026-01-27 | — | — | US | disclosed |
| EP-4674268-A2 | INSECTICIDAL PROTEINS FROM PLANTS AND METHODS FOR THEIR USE | Pioneer Hi-Bred International, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4661876-A1 | METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF | University of Miami (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-3764798-B1 | INSECTICIDAL PROTEINS FROM PLANTS AND METHODS FOR THEIR USE | PIONEER HI BRED INT (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250327089-A1 | NOVEL INSECTICIDAL PROTEINS FROM PLANTS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250242086-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3635373-B1 | ANALYSIS OF SINGLE CELL MECHANICAL PHENOTYPING FOR METASTATIC DETECTION | UNIV MARYLAND (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| CN-114763376-A | Insecticidal proteins and methods of use thereof | 先锋国际良种公司 | 2022-07-19 | — | — | CN | disclosed |
| EP-3895712-B1 | ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | ONK THERAPEUTICS LTD (IE) | 2022-06-22 | — | — | EP | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| US-20220072013-A1 | Pharmaceutical Combinations for the Treatment of Cancer | CA*TX, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | IL23R 1691/4885REN 593/4885OPRM1 90/4885 |
| US-20220072013-A1 | Pharmaceutical Combinations for the Treatment of Cancer | APC, TP53, VHL | IL23R 1567/4885REN 3694/4885OPRM1 4771/4885 |
| US-12534536-B2 | Natural killer cells expressing a chimeric antigen receptor that binds CD38 | TNFRSF9, TNFRSF1A, CD40 | IL23R 54/4885REN 3987/4885OPRM1 3513/4885 |
| US-20250327089-A1 | NOVEL INSECTICIDAL PROTEINS FROM PLANTS | RNGTT, CACYBP, CNBP | IL23R 4774/4885REN 4435/4885OPRM1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.